top
Search terms
Results 11 - 20 of 216 - ordered by :
Pages: 1 2 3 4 5 6 7 ... 22
Escardio

Genotype-guided oral P2Y12 inhibition reduces bleeding without raising clotting risk in heart attack patients undergoing stent implantation, according to late breaking results from the POPular ...

Date : 03/09/2019
Escardio

Discharge of patients with suspected acute coronary syndromes under a 0- and 1-hour high-sensitivity cardiac troponin T (hs-cTnT) protocol is safe, according to late breaking results from the ...

Date : 03/09/2019
Escardio

(1) Principal investigator Dr Satoshi Yasuda of the National Cerebral and Cardiovascular Centre, Suita, Japan said: “This data supports the guideline recommendation to use oral anticoagulant ...

Date : 02/09/2019
Escardio

“How to best manage the non-culprit lesions in patients with ST-elevation myocardial infarction (STEMI) and multivessel coronary artery disease has been a dilemma for some time,” explains ...

Date : 02/09/2019
Escardio

Dr. Neumann explains, “Over recent decades, the management of patients with ACS has changed substantially. Throughout the 10-year period, the in-hospital mortality was 6.3%, being highest for ...

Date : 02/09/2019
Escardio

According to current clinical practice guidelines, prasugrel and ticagrelor have equal, Class I recommendations for use following percutaneous coronary intervention (PCI) in acute coronary syndromes ...

Date : 02/09/2019
Escardio

Up to 50% of patients with ST-segment elevation myocardial infarction (STEMI) have multivessel coronary artery disease. Prior randomised trials found declines in composite outcomes with non-culprit ...

Date : 01/09/2019
Escardio

Senior author Professor Philippe Gabriel Steg of Hospital Bichat, Paris, France said: “Treatment with ticagrelor and aspirin also increased major bleeding relative to aspirin alone, but there ...

Date : 01/09/2019
Escardio

An early rule-out pathway for myocardial infarction reduces length of stay and hospital admissions without increasing adverse cardiac events, according to late breaking results from the HiSTORIC ...

Date : 01/09/2019
Escardio

Prasugrel is superior to ticagrelor for reducing ischaemic events in patients with acute coronary syndrome and a planned invasive strategy. Both drugs are recommended over clopidogrel for 12 months ...

Date : 01/09/2019